ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2969

10 Year Retrospective Analysis of 276 Cases of Histopathologically Confirmed Leukocytoclastic Vasculitis

Shazdeh Butt1 and Thomas Olenginski2, 1Rheumatology, Geisinger Medical Center, Danville, PA, 2Department of Rheumatology, Geisinger Medical Center, Danville, PA

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: angiitis, biopsies, Cutaneous manifestations, skin and vasculitis

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 15, 2016

Session Title: Vasculitis - Poster III: Rarer Vasculitides

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: We identified leukocytoclastic vasculitis (LCV) patients seen over 10 years at our institution.  Aims included 1) define cause; 2) record lab, imaging, and ancillary tests used in evaluation; 3) tabulate Medicare reimbursement costs.

Methods: All biopsy-confirmed LCV cases from 1/1/2004 to 12/31/2014 were identified by analysis of suspected cases in Dermatopathology registry.  We analyzed pathology reports and only those cases with definite LCV on biopsy and available electronic health record (EHR) progress notes were included in this analysis.  Clinical, epidemiologic, and other variables were then extracted from EHR and costs recorded.  We calculated total lab and imaging costs, plus average costs/patient.  Additionally, we determined if Rheumatology or other consultations were performed.

Results: Mean age of LCV cohort was 53.1 years, with 161 women, 115 men.  Immunofluorescence was performed in 161/276 (58 %) biopsies.  LCV etiology was divided into 6 major categories (Table 1), with Idiopathic in 41 %; Vasculitis in 32 %; Drug-induced 10 %; Infection-related 9 %; CTD 4 %; malignancy-related 3 %.  Vasculitis or CTD accounted for 101/276 cases (Table 1).  More than 50 % of Vasculitis cases were due to HSP.  The HSP group mean age was 33 years, with 23/52 (44 %) being < 20 years old.  Surprisingly, 56 % of our HSP patients were adults.  Specific lab and imaging tests are shown in Tables 2 and 3.  Total lab costs for all patients were $36,161 or $131/patient.  Total imaging costs were $85,700 or $311/patient. Rheumatology accounted for 138/147 requested consultations (94%) at cost of $20,806.  Nine renal biopsies were performed at $10,782 cost.  Glucocorticoid therapy was used in 148/276 or 54 % cases.    

Table 1: Causes of LCV (N= 276)
1. Idiopathic 113 41%
2. Vasculitis 89 32%
  HSP 52  
  Cryoglobinemic 6  
  ANCA associated 10  
  PAN 6  
  Arteritis not otherwise specified 15  
3. Drugs 28 10%
4. Infections 25 9%
  Hepatitis C 4  
  Streptococcus 4  
  Staphylococcus 5  
  C-difficile 1  
  Viral 3  
  Other 8  
5. CTDs 12 4%
  RA 5  
  SLE 4  
  Other 3  
6. Malignancy 9 3%
  Solid Organ 5  
  Multiple Myeloma 2  
  MDS 2  

 

Table 2: Labs/Medicare Reimbursement (Costs)
  Lab N = 276 Percent Ordered
1 CBC 264 95.6%
2 BMP 263 95.2%
3 LFTs 245 88.7%
4 ESR/ CRP 210 76%
5 ANA 204 73.9%
6 Hepatitis Testing 148 53.6%
7 UA 234 84.7%
8 Streptococcal  Testing 34 12.3%
Cost *Total Imaging costs = $85,700 276 $311/patient

 

Table 3: Imaging Tests/Medicare Reimbursement (Costs)
  Test N = 276 Percent Ordered
1 CXR 113 40.9%
2 Echocardiogram 56 20.3%
3 CT Abdomen/Pelvis 51 18.3%
4 CT Chest 48 17.4%
Cost *Total Imaging costs = $85,700 276 $311/patient

 

Conclusion: Our report of 276 biopsy-confirmed LCV patients seen over this 10 year period may be the largest analysis so performed.   Idiopathic (41 %) and Vasculitis (32 %) were the most common causes.   Definite Rheumatic disease (Vasculitis/CTD) was identified as cause of LCV in 36 % of patients. Within the Vasculitis group, HSP comprised more than 50 % of that subgroup, with a surprising 56 % adult-HSP.   Importantly, our study includes a unique cost analysis for lab, diagnostic imaging, consultations, and renal biopsy.  The evaluation of LCV remains clinically challenging and more costly than previously reported.  


Disclosure: S. Butt, None; T. Olenginski, None.

To cite this abstract in AMA style:

Butt S, Olenginski T. 10 Year Retrospective Analysis of 276 Cases of Histopathologically Confirmed Leukocytoclastic Vasculitis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/10-year-retrospective-analysis-of-276-cases-of-histopathologically-confirmed-leukocytoclastic-vasculitis/. Accessed March 27, 2023.
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/10-year-retrospective-analysis-of-276-cases-of-histopathologically-confirmed-leukocytoclastic-vasculitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences